These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1646 related items for PubMed ID: 26082625

  • 1. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Thach C, Patalano F, Banerji D, LANTERN Investigators.
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
    Dahl R, Jadayel D, Alagappan VK, Chen H, Banerji D.
    Int J Chron Obstruct Pulmon Dis; 2013; 8():501-8. PubMed ID: 24159259
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.
    Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D'Andrea P, Chen H, Banerji D.
    Lancet Respir Med; 2013 Mar; 1(1):51-60. PubMed ID: 24321804
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study.
    Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Patalano F, Banerji D.
    COPD; 2016 Dec; 13(6):686-692. PubMed ID: 27715335
    [Abstract] [Full Text] [Related]

  • 5. Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis.
    Vogelmeier C, Zhong N, Humphries MJ, Mezzi K, Fogel R, Bader G, Patalano F, Banerji D.
    Int J Chron Obstruct Pulmon Dis; 2016 Dec; 11():3189-3197. PubMed ID: 28008244
    [Abstract] [Full Text] [Related]

  • 6. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.
    Wedzicha JA, Zhong N, Ichinose M, Humphries M, Fogel R, Thach C, Patalano F, Banerji D.
    Int J Chron Obstruct Pulmon Dis; 2017 Dec; 12():339-349. PubMed ID: 28176893
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.
    Frith PA, Ashmawi S, Krishnamurthy S, Gurgun A, Hristoskova S, Pilipovic V, Hamann AM, Backer A, Olsson P, Kostikas K, Diaz DV, FLASH Investigators.
    Respirology; 2018 Dec; 23(12):1152-1159. PubMed ID: 30074294
    [Abstract] [Full Text] [Related]

  • 8. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
    Horita N, Kaneko T.
    Int J Chron Obstruct Pulmon Dis; 2015 Dec; 10():813-22. PubMed ID: 25960646
    [Abstract] [Full Text] [Related]

  • 9. Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study.
    Kaplan A, Chapman KR, Anees SM, Mayers I, Rochdi D, Djandji M, Préfontaine D, McIvor A.
    Int J Chron Obstruct Pulmon Dis; 2019 Dec; 14():249-260. PubMed ID: 30718952
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
    Buhl R, Gessner C, Schuermann W, Foerster K, Sieder C, Hiltl S, Korn S.
    Thorax; 2015 Apr; 70(4):311-9. PubMed ID: 25677679
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
    Vincken W, Aumann J, Chen H, Henley M, McBryan D, Goyal P.
    Int J Chron Obstruct Pulmon Dis; 2014 Apr; 9():215-28. PubMed ID: 24596459
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
    Dahl R, Chapman KR, Rudolf M, Mehta R, Kho P, Alagappan VK, Chen H, Banerji D.
    Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
    [Abstract] [Full Text] [Related]

  • 13. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
    Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF, FLAME Investigators.
    N Engl J Med; 2016 Jun 09; 374(23):2222-34. PubMed ID: 27181606
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.
    Vogelmeier CF, Gaga M, Aalamian-Mattheis M, Greulich T, Marin JM, Castellani W, Ninane V, Lane S, Nunez X, Patalano F, Clemens A, Kostikas K, CRYSTAL study investigators.
    Respir Res; 2017 Jul 18; 18(1):140. PubMed ID: 28720132
    [Abstract] [Full Text] [Related]

  • 15. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD.
    Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S, Banerji D, Fogel R.
    Int J Chron Obstruct Pulmon Dis; 2017 Jul 18; 12():1325-1337. PubMed ID: 28496316
    [Abstract] [Full Text] [Related]

  • 16. FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.
    Mahler DA, Kerwin E, Ayers T, FowlerTaylor A, Maitra S, Thach C, Lloyd M, Patalano F, Banerji D.
    Am J Respir Crit Care Med; 2015 Nov 01; 192(9):1068-79. PubMed ID: 26177074
    [Abstract] [Full Text] [Related]

  • 17. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease.
    Frampton JE.
    Drugs; 2014 Mar 01; 74(4):465-88. PubMed ID: 24604791
    [Abstract] [Full Text] [Related]

  • 18. Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.
    Vogelmeier CF, Chapman KR, Miravitlles M, Roche N, Vestbo J, Thach C, Banerji D, Fogel R, Patalano F, Olsson P, Kostikas K, Wedzicha JA.
    Int J Chron Obstruct Pulmon Dis; 2018 Mar 01; 13():1125-1134. PubMed ID: 29692607
    [Abstract] [Full Text] [Related]

  • 19. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
    Beeh KM, Korn S, Beier J, Jadayel D, Henley M, D'Andrea P, Banerji D.
    Respir Med; 2014 Apr 01; 108(4):584-92. PubMed ID: 24534204
    [Abstract] [Full Text] [Related]

  • 20. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI, Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Siddiqui S, Anzueto A, Zhu H.
    Int J Chron Obstruct Pulmon Dis; 2016 Apr 01; 11():1921-8. PubMed ID: 27574416
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 83.